|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.2350 - 0.2350|
|52 Week Range||0.1840 - 0.4700|
|Beta (5Y Monthly)||-0.19|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Amarillo, TX, Feb. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that its China licensing partner, Xiamen Weiyang Pharmaceutical Co., Ltd. (“Xiamen Weiyang”), has begun initiating the sharing of proprietary clinical research information with health officials in China to potentially explore the effect of ABI’s low-dose oral interferon in combating the spread of novel coronavirus, now officially known as Covid-19, along with other related viral indications such as influenza. There are currently no approved therapeutics or vaccines for Covid-19.
Amarillo, TX, July 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that it has entered into a Term Sheet outlining a licensing and royalty agreement with Xiamen Weiyang Pharmaceutical Co., Ltd., a company organized under the laws of the People’s Republic of China (“Xiamen Weiyang”), setting forth the proposed terms for a cooperative development and licensing venture in China. The consummation of the proposed transaction is contingent on a mutually agreeable definitive agreement. Dr. Stephen T. Chen, ABI’s CEO, stated, “We are pleased to announce this proposed venture with Xiamen Weiyang.